Reference number(s) 2143-A, 2682-A

SPECIALTY GUIDELINE MANAGEMENT

VIEKIRA PAK (ombitasvir/paritaprevir/ritonavir/dasabuvir)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indications

Viekira Pak is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV):

- A. genotype 1b without cirrhosis or with compensated cirrhosis
- B. genotype 1a without cirrhosis or with compensated cirrhosis for use in combination with ribavirin (RBV)

All other indications are considered experimental/investigational and not medically necessary.

II. EXCLUSIONS

Coverage will not be provided for members with decompensated cirrhosis/moderate or severe hepatic impairment (Child Turcotte Pugh Class B or C).

Note: When the requested drug is being used in a combination therapy regimen, exclusions to the other antiviral drugs also apply.

III. CRITERIA FOR INITIAL APPROVAL

A. Chronic hepatitis C virus infection, in combination with ribavirin

Note: Members with mixed genotype 1 infection or unknown genotype 1 subtype should follow the criteria for approval for genotype 1a infection.

1. Genotype 1a infection

- i. Authorization of up to 12 weeks total may be granted for members without cirrhosis who are either of the following:
 - a. Treatment-naïve
 - b. Failed prior treatment with peginterferon alfa (PEG-IFN) and RBV
- ii. Authorization of up to 24 weeks total may be granted for members with compensated cirrhosis who are either of the following:
 - a. Treatment-naïve
 - b. Failed prior treatment with PEG-IFN and RBV

2. Recurrent HCV infection post liver transplantation

Authorization of up to 24 weeks total may be granted for members with recurrent HCV infection post liver transplantation who meet all of the following criteria:

- i. Genotype 1 infection (irrespective of subtype)
- ii. Metavir fibrosis score of 2 or lower

Viekira 2143-A, 2682-A SGM P2021.docx

© 2021 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.



B. Chronic hepatitis C virus infection, without ribavirin **Genotype 1b infection**

Authorization of up to 12 weeks total may be granted for members without cirrhosis or with compensated cirrhosis who are either of the following:

- 1. Treatment-naïve
- 2. Failed prior treatment with PEG-IFN and RBV

C. HCV and HIV coinfection


Authorization may be granted for members with HCV and HIV coinfection when the criteria for approval of the requested regimen in section A or B above are met.

IV. CONTINUATION OF THERAPY

All members (including new members) requesting authorization for continuation of therapy must meet all initial authorization criteria.

V. REFERENCES

1. Viekira Pak [package insert]. North Chicago, IL: AbbVie Inc.; December 2019.



© 2021 CVS Caremark. All rights reserved.

